Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus

Piazuelo, Elena; Jiménez, Pilar; Strunk, Mark; Santander, Sonia; García, Asunción; Esteva, Francisco J.; Lanas, Ángel

doi:10.1016/j.prostaglandins.2006.09.002

Cited by 28 publications

(32 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cells were sonicated in 1 ml PBS plus indomethacin and centrifuged. PGE 2 extraction was performed using ODS (octadecyl silica) columns (Sep-Pack C18; Waters) as previously described [13], and PGE 2 concentration was measured using an EIA kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA).…”

Section: Measurement Of Prostaglandin E 2 Levelsmentioning

confidence: 99%

Acetylsalicylic Acid Exhibits Antitumor Effects in Esophageal Adenocarcinoma Cells In Vitro and In Vivo

Piazuelo

Esquivias

et al. 2016

Dig Dis Sci

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Measurement Of Prostaglandin E 2 Levelsmentioning

confidence: 99%

Acetylsalicylic Acid Exhibits Antitumor Effects in Esophageal Adenocarcinoma Cells In Vitro and In Vivo

Piazuelo

Esquivias

et al. 2016

Dig Dis Sci

Self Cite

View full text Add to dashboard Cite

show abstract

“…The muscle strips were incubated for 24 h with vehicle control (DMSO), and the specific antagonists to EP1 (SC-52342, Enzo, Plymouth Meeting, PA), EP1/EP2 (AH6809, Enzo), EP3 (L-798106, Tocris Bioscience, Ellisville, MO) and EP4 (ONO-AE 3-208, Haoyuan Chemexpress, Shanghai, China), separately. The concentration of 10 Ϫ5 M was chosen for all the antagonists because this was found effective in blocking respective EP receptor subtypes (4,18,32,48). Incubation with EP2 or EP4 antagonists did not significantly change colonic circular muscle contractility in sham control tissue (Fig.…”

Section: Involvement Of Ep Receptor Subtypes In the Regulation Of Colmentioning

confidence: 99%

Prophylactic and therapeutic benefits of COX-2 inhibitor on motility dysfunction in bowel obstruction: roles of PGE₂ and EP receptors

Lin

Sarna

Shi

2012

American Journal of Physiology-Gastrointestinal and Liver Physi

View full text Add to dashboard Cite

We reported previously that mechanical stretch in rat colonic obstruction induces cyclooxygenase (COX)-2 expression in smooth muscle cells. The aims of the present study were to investigate whether in vivo treatment with COX-2 inhibitor has prophylactic and therapeutic effects on motility dysfunction in colon obstruction, and if so what are the underlying mechanisms. Partial colon obstruction was induced with a silicon band in the distal colon of 6 -8-wk-old Sprague-Dawley rats; obstruction was maintained for 3 days or 7 days. Daily administration of COX-2 inhibitor NS-398 (5 mg/kg) or vehicle was started before or after the induction of obstruction to study its prophylactic and therapeutic effects, respectively. The smooth muscle contractility was significantly suppressed, and colonic transit rate was slower in colonic obstruction. Prophylactic treatment with NS-398 significantly prevented the impairments of colonic transit and smooth muscle contractility and attenuated fecal collection in the occluded colons. When NS-398 was administered therapeutically 3 days after the initiation of obstruction, the muscle contractility and colonic transit still improved on day 7. Obstruction led to marked increase of COX-2 expression and prostaglandin E 2 (PGE2) synthesis. Exogenous PGE2 decreased colonic smooth muscle contractility. All four PGE2 E-prostanoid receptor types (EP1 to EP4) were detected in rat colonic muscularis externa. Treatments with EP1 and EP3 antagonists suppressed muscle contractility in control tissue but did not improve contractility in obstruction tissue. On the contrary, the EP2 and EP4 antagonists did not affect control tissue but significantly restored muscle contractility in obstruction. We concluded that our study shows that COX-2 inhibitor has prophylactic and therapeutic benefits for motility dysfunction in bowel obstruction. PGE2 and its receptors EP2 and EP4 are involved in the motility dysfunction in obstruction, whereas EP1 and EP3 mediate PGE2 regulation of colonic smooth muscle contractile function in normal state.

show abstract

“…Classically the EP 1 and EP 3 receptors couple to Gαq and Gαi to activate Ca 2+ signalling and inhibition of adenylyl cyclase, respectively. The EP 2 and EP 4 receptors couple to Gαs to stimulate adenylyl cyclase and activate cAMP/protein kinase A (PKA) signaling (21)(22)(23)(24)(25) (30). So far, most studies with NSAIDs and selective COX-2 inhibitors have focused on their effect in the chemoprevention of dysplasia or esophageal adenocarcinoma in Barrett's esophagus patients, but the potential of COX inhibition for treatment of esophageal adenocarcinoma once established, has been scarcely explored (31).…”

Section: Introductionmentioning

confidence: 99%

Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice

et al. 2011

Self Cite

View full text Add to dashboard Cite

Abstract. Cyclooxygenase (COX) inhibition has been shown to prevent the development of esophageal adenocarcinoma (EAC). However, the potential of this approach for treatment of established cancer has been poorly investigated. Our objective was to determine whether non-selective or selective inhibition of the COX pathway affects the growth of esophageal adenocarcinoma xenografts in nude mice. A human esophageal adenocarcinoma xenograft model was established by subcutaneous inoculation of OE33 cells in nude mice. Small tumor slices harvested from four OE33 xenografts were implanted in the flanks of new mice that were randomized to different treatments (6 animals per group): indomethacin (3 mg/kg/day), parecoxib (0.11 and 0.22 mg/ kg/day) or a selective prostaglandin E 2 receptor antagonist (AH-23848B, 1 mg/kg/day). For each treatment, a control group of 6 animals (vehicle) carrying xenografts from the same OE33 tumor was included. Tumor growth was measured twice a week. After 8 weeks mice were euthanized. Tumors were assessed by histological analysis, mRNA expression of COX isoenzymes, PGE 2 receptors and PGE 2 content. All OE33 tumors were poorly differentiated esophageal adenocarcinomas. Tumors expressed COX-2, EP 1 , EP 2 and EP 4 receptor mRNA. Treatment with parecoxib, higher dose or indomethacin significantly inhibited tumor growth. Furthermore, indomethacin induced tumor regression (74 vs 582% in control animals; p<0.01). However, AH-23848B or parecoxib low dose failed to affect tumor growth significantly. PGE 2 content in tumors was significantly decreased by high-dose parecoxib and indomethacin. Indomethacin and parecoxib inhibit the growth of human esophageal adenocarcinoma xenografts in nude mice, which suggests a potential role for NSAIDs or selective COX-2 inhibitors for EAC chemotherapy.

show abstract

Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus

Cited by 28 publications

References 37 publications

Acetylsalicylic Acid Exhibits Antitumor Effects in Esophageal Adenocarcinoma Cells In Vitro and In Vivo

Acetylsalicylic Acid Exhibits Antitumor Effects in Esophageal Adenocarcinoma Cells In Vitro and In Vivo

Prophylactic and therapeutic benefits of COX-2 inhibitor on motility dysfunction in bowel obstruction: roles of PGE₂ and EP receptors

Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice

Contact Info

Product

Resources

About

Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus

Cited by 28 publications

References 37 publications

Acetylsalicylic Acid Exhibits Antitumor Effects in Esophageal Adenocarcinoma Cells In Vitro and In Vivo

Acetylsalicylic Acid Exhibits Antitumor Effects in Esophageal Adenocarcinoma Cells In Vitro and In Vivo

Prophylactic and therapeutic benefits of COX-2 inhibitor on motility dysfunction in bowel obstruction: roles of PGE2 and EP receptors

Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice

Contact Info

Product

Resources

About

Prophylactic and therapeutic benefits of COX-2 inhibitor on motility dysfunction in bowel obstruction: roles of PGE₂ and EP receptors